Literature DB >> 2273273

Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS.

C Montalban1, J L Calleja, A Erice, F Laguna, B Clotet, D Podzamczer, J Cobo, J Mallolas, M Yebra, A Gallego.   

Abstract

We describe 40 HIV-seropositive patients who developed visceral leishmaniasis. All the patients lived in areas endemic for visceral leishmaniasis and belonged to groups at risk for AIDS. Twenty-three patients (57.2%) had definitive AIDS before or after diagnosis of leishmaniasis and 77.5% were classified as belonging to CDC group IV. Fever was present in 95% patients and enlargement of the liver and/or spleen in 92.5%. Lymphopenia was found in 78.3%, depression of the absolute number of CD4 lymphocytes in 90% and depression of the CD4 to CD8 ratio in all evaluated cases but leishmania antibodies were found in only 35.2%. Parasites were demonstrated in the bone marrow or liver in every case. Thirty patients (75%) showed an initial good response to antimonial drugs, although the leishmaniasis followed a chronic or relapsing course in 17 (42.5%). HIV-related mortality was 40%. A significant correlation was found only between the relapsing course of the disease and mortality. In a multivariate linear regression model, the relapsing course was the only variable that influenced mortality. Visceral leishmaniasis is an opportunistic disease that should be suspected in HIV-infected patients. We suggest that it should be included in the CDC group IV C-1 and considered as a disease indicative of AIDS.

Entities:  

Mesh:

Year:  1990        PMID: 2273273     DOI: 10.1016/0163-4453(90)93933-j

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  26 in total

1.  Fever, weight loss, and night sweats: infection or malignancy?

Authors:  A J Winter; M J Wiselka; J T Wilde; K W Radcliffe
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

2.  Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model.

Authors:  M Paul; R Durand; H Fessi; D Rivollet; R Houin; A Astier; M Deniau
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Persistent polyclonal B lymphocytosis with Epstein-Barr virus antibodies and subsequent malignant pulmonary blastoma.

Authors:  D E Wyatt; P V Coyle
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

4.  Visceral leishmaniasis in human immunodeficiency virus disease.

Authors:  C Montalban
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

5.  Immune reactivity to fractionated Leishmania aethiopica antigens during coinfection with human immunodeficiency virus type 1.

Authors:  S C Arya
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

6.  Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients.

Authors:  G Angarano; P Maggi; S L Coppola; R L Cavaliere
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

7.  Pyrexia of undetermined origin in advanced HIV disease.

Authors:  C M Tang; C P Conlon; R F Miller
Journal:  Genitourin Med       Date:  1997-08

8.  Diagnosis of visceral leishmaniasis in HIV-infected patients.

Authors:  I Gasser; A Jaén; J González; E Ribera
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

9.  PCR and in vitro cultivation for detection of Leishmania spp. in diagnostic samples from humans and dogs.

Authors:  A Mathis; P Deplazes
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

10.  Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral Leishmaniasis in immunocompromised patients.

Authors:  R Piarroux; F Gambarelli; H Dumon; M Fontes; S Dunan; C Mary; B Toga; M Quilici
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.